Selzentry, Celsentri(maraviroc)
Celsentri, Selzentry (maraviroc) is a small molecule pharmaceutical. Maraviroc was first approved as Selzentry on 2007-08-06. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. The pharmaceutical is active against C-C chemokine receptor type 5.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Selzentry (generic drugs available since 2022-02-07)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| selzentry | New Drug Application | 2022-11-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hiv infections | EFO_0000764 | D015658 | B20 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MARAVIROC, SELZENTRY, VIIV HLTHCARE | |||
| 2024-04-30 | PED | ||
| 2023-10-30 | NPP | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
134 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 10 | 13 | 14 | 18 | 9 | 59 |
| Hiv | D006678 | O98.7 | 4 | 5 | 1 | 9 | 6 | 24 | |
| Healthy volunteers/patients | — | 8 | 1 | — | 1 | — | 10 | ||
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | 2 | 4 | 2 | 8 |
| Inflammation | D007249 | — | — | 1 | 1 | — | 2 | ||
| Hiv-2 | D015498 | — | — | — | 1 | 1 | 2 | ||
| Proteinuria | D011507 | HP_0000093 | R80 | — | — | — | 1 | — | 1 |
| Heart disease risk factors | D000082742 | — | — | — | 1 | — | 1 | ||
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | 1 | — | 1 |
| Hepatitis c | D006526 | B19.2 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv-1 | D015497 | — | 2 | 3 | — | 1 | 6 | ||
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 3 | 1 | — | — | 3 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | 1 | 2 |
| Aids dementia complex | D015526 | EFO_0002608 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | D89.81 | 2 | 3 | — | — | — | 3 | |
| Covid-19 | D000086382 | U07.1 | 1 | 2 | — | — | — | 3 | |
| Hematopoietic stem cell transplantation | D018380 | 1 | 2 | — | — | — | 2 | ||
| Hematologic neoplasms | D019337 | 1 | 2 | — | — | — | 2 | ||
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | — | 1 | — | — | — | 1 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | 1 | |
| Hodgkin disease | D006689 | C81 | — | 1 | — | — | — | 1 | |
| Follicular lymphoma | D008224 | C82 | — | 1 | — | — | — | 1 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | — | 1 | — | — | — | 1 | |
| B-cell lymphoma | D016393 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | 2 | — | — | — | 1 | 3 | ||
| Infections | D007239 | EFO_0000544 | 2 | — | — | — | — | 2 | |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Mycobacterium avium complex | D015269 | 1 | — | — | — | — | 1 | ||
| Hypertriglyceridemia | D015228 | EFO_0004211 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Immune reconstitution inflammatory syndrome | D054019 | D89.3 | — | — | — | — | 1 | 1 | |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | — | — | — | 1 | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MARAVIROC |
| INN | maraviroc |
| Description | Maraviroc is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4,4-difluorocyclohexanecarboxylic acid and the primary amino group of (1S)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropylamine. An antiretroviral drug, it prevents the interaction of HIV-1 gp120 and chemokine receptor 5 (CCR5) necessary for CCR5-tropic HIV-1 to enter cells. It has a role as an antiviral drug, a chemokine receptor 5 antagonist and a HIV fusion inhibitor. It is an azabicycloalkane, an organofluorine compound, a member of triazoles and a monocarboxylic acid amide. |
| Classification | Small molecule |
| Drug class | antivirals; antivirals, chemokine receptor (CCR) antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1 |
Identifiers
| PDB | 4MBS |
| CAS-ID | 376348-65-1 |
| RxCUI | 620216 |
| ChEMBL ID | CHEMBL1201187 |
| ChEBI ID | 63608 |
| PubChem CID | 3002977 |
| DrugBank | DB04835 |
| UNII ID | MD6P741W8A (ChemIDplus, GSRS) |
Target
Agency Approved
CCR5
CCR5
Organism
Homo sapiens
Gene name
CCR5
Gene synonyms
CMKBR5
NCBI Gene ID
Protein name
C-C chemokine receptor type 5
Protein synonyms
C-C motif chemokine receptor 5 A159A, CD195, chemokine (C-C motif) receptor 5, chemokine receptor CCR5, chemokine recptor CCR5 Delta32, CHEMR13, HIV-1 fusion coreceptor, mutant C-C motif chemokine receptor
Uniprot ID
Mouse ortholog
—
—
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,579 documents
View more details
Safety
Black-box Warning
Black-box warning for: Selzentry
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
726 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more